EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters

Joshua Marceau, David Safronetz, Cynthia Martellaro, Andrea Marzi iD, Kyle Rosenke, Heinz Feldmann iD

Viruses · 2024

DOI: 10.3390/v16020279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Joshua Marceau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamil…. Hauptthemen laut MEDLINE: Orthohantavirus, Ebolavirus, Ebola Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID - Intramural research Program, Intramural Research Program of the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orthohantaviruses may cause hemorrhagic fever with renal syndrome or hantavirus cardiopulmonary syndrome. Andes virus (ANDV) is the only orthohantavirus associated with human–human transmission. Therefore, emergency vaccination would be a valuable public health measure to combat ANDV-derived infection clusters. Here, we utilized a promising vesicular stomatitis virus (VSV)-based vaccine to advance the approach for emergency applications. We compared monovalent and bivalent VSV vectors containing the Ebola virus (EBOV), glycoprotein (GP), and ANDV glycoprotein precursor (GPC) for protective efficacy in pre-, peri- and post-exposure immunization by the intraperitoneal and intranasal routes. Inclusion of the EBOV GP was based on its favorable immune cell targeting and the strong innate responses elicited by the VSV-EBOV vaccine. Our data indicates no difference of ANDV GPC expressing VSV vectors in pre-exposure immunization independent of route, but a potential benefit of the bivalent VSVs following peri- and post-exposure intraperitoneal vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrthohantavirusEbolavirusEbola VaccinesCricetinaeAnimalsHumansVesiculovirusVesicular stomatitis Indiana virusGlycoproteinsAntibodies, Viral

Stichwörter der Autor:innen

Andes virusOrthohantavirusSyrian hamsterVSVemergency vaccinationvaccine

Substanzen

Ebola VaccinesGlycoproteinsAntibodies, Viral

Autor:innen und Institutionen

  • Laboratory of Virology, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
  • Department of Biomedical and Pharmaceutical Sciences, The University of Montana, Missoula, MT 59812, USA.

ORCID-Profile: Andrea Marzi, Heinz Feldmann

Förderung

  • NIAID - Intramural research Program
  • Intramural Research Program of the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Zitieren

APA

Marceau, J., Safronetz, D., Martellaro, C., Marzi, A., Rosenke, K., & Feldmann, H. (2024). Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters. Viruses. https://doi.org/10.3390/v16020279

Vancouver

Marceau J, Safronetz D, Martellaro C, Marzi A, Rosenke K, Feldmann H. Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters. Viruses. 2024. doi:10.3390/v16020279

BibTeX
@article{Marceau2024,
  author = {Marceau, Joshua and Safronetz, David and Martellaro, Cynthia and Marzi, Andrea and Rosenke, Kyle and Feldmann, Heinz},
  title = {Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16020279}
}
Kostenlos starten →